Adolor Corporation ADLR
-
Why Big Pharma Doesn't Really Need (Or Even Want) A Pipeline
By James Brumley : Warning: What you're about to read will ruffle some feathers. That's not the intent - just the likely effect. And yes, there are always exceptions. The problem is, there aren't enough exceptions. Though it started to happen in 2011, this year is the one that starts the really ...
-
Biotech-Focused Baker Bros.' Top Q3 Picks
By Ganaxi Small Cap Movers : New York-based Hedge Fund Baker Bros. Advisors LLC, as of the most recent SEC 13-F filing for the September 2011 quarter , had $2.1 billion in equity assets, almost all invested in the biotech sector, including 80% in small cap and micro cap equities, and the remaining
-
Adolor's Takeover Bid From Cubist An Attractive Deal For Investors
… the Proposed Acquisition Cubist ( CBST ) announced today that it had signed a definitive agreement to acquire Adolor ( ADLR ). Adolor has been one of my four current recommendations . My price target was $4.50 in 2013, based on sales and earnings …
-
Cubist's Over-The-Top Offer To Acquire Adolor Likely To Ignite The Opioid Space
… CBST ) over-the-top premium offer to acquire Adolor Corp. ( ADLR ) for $4.25 per share in cash (it closed Friday ..... patient comfort as well as reduced hospitalization times. Adolor , which in Latin means “without pain,” has a …
-
Cubist Fills Its Sales Bag And Pipeline With Adolor
By Stephen Simpson : Stuck in a trading range for about five years, Cubist Pharmaceuticals ( CBST ) has had a pretty good year in 2011. The company resolved a patent dispute with Teva Pharmaceuticals ( TEVA ) on reasonably good terms, got some patent extensions that should further boost its profit
-
Premarket gainers: [[ ADLR ]] +132%. [[HS]] +33%. [[EXEL]] +26%. [[RNOW]] +19%. [[SVM]] +6%. [[LYG]] +5%. [[RIO]] +5%. [[CAT]] +5%. [[FCX]] +4%. [[ALU]] +3%. [[BHP]] +3%. [[YHOO]] +3%.Losers: [[SXCI]] ...
Premarket gainers: ADLR +132% . HS +33% . EXEL +26% . RNOW +19% . SVM +6% . LYG +5% . RIO +5% . CAT +5% . FCX +4% . ALU +3% . BHP +3% . YHOO +3% . Losers: SXCI -20% . NBG -16% . MTG -4% . Post your comment!
-
Cubist Pharmaceuticals (CBST) agrees to acquire Adolor ( ADLR ) for ~$190M in cash, or $4.25/share, and will make an additional contigent payment of up to $4.25/share for certain milestones related to ...
… Pharmaceuticals ( CBST ) agrees to acquire Adolor ( ADLR ) for ~$190M in cash, or $4 ..... for certain milestones related to Adolor 's ADL5945, a potential treatment ..... chronic opioid induced constipation. ADLR +134.9% premarket. 1 comment …
-
Focus On Entereg; Reiterating Buy On Adolor
… Stocks : Investment Thesis I upgraded Adolor ( ADLR ) to a BUY after the company announced ..... marketing agreement with Glaxo to Adolor assuming all responsibility for marketing ..... investor conference and spoke with Adolor ’s management on Complete Story …
-
Biotech Clinical Trials Updates: Biogen, Abbott and Adolor
By Roger Newman : This is one in a series of articles that highlight recent clinical trial updates for new drugs in the FDA approval process. A brief overview of the FDA approval process can be found here . Biogen Idex ( BIIB ) and Abbott ( ABT ) reported top-line results from a Phase 2b trial to
-
Healthcare: 4 Technical Set-Ups With High Analyst Recommendations
… analyst recommendations. We kick things off with the Adolor Corporation ( ADLR ) who recently reported net sales of ENTEREG® of ..... Murray Carret & Co. assumed coverage on shares of Adolor with a BUY rating and $4 price target. As noted …